Fran Klemens

Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA.

Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA.

Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA.

Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA.